Lataa...

Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer

Trastuzumab improves outcomes among patients with HER2-positive breast cancer but is associated with a risk of treatment-induced cardiotoxicity (TIC). It is unclear how frequently TIC leads to trastuzumab interruption outside of prospective trials, and how TIC is managed in clinical practice. Patien...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Breast Cancer Res Treat
Päätekijät: Yu, Anthony F., Yadav, Nandini U., Lung, Betty Y., Eaton, Anne A., Thaler, Howard T., Hudis, Clifford A., Dang, Chau T., Steingart, Richard M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4970316/
https://ncbi.nlm.nih.gov/pubmed/25552363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3253-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!